肺高血压中的纤维细胞:作用和分子机制
Hui Zhang1, Min Li1, Cheng-Jun Hu1,2
1Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA.
Cells
|June 19, 2024
概括
肺高血压 (PH) 涉及显著的血管改造. 进发性纤维细胞,不仅仅是亲密和介质细胞,通过持续的增殖和炎症,关键地驱动PH病原体.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 肺部医学 肺部医学
背景情况:
- 纤维细胞是组织结构,平衡和通过细胞外矩阵重塑疾病的关键.
- 肺高血压 (PH) 的特点是肺血管重塑,影响内脏,介质和冒险.
- 进发性纤维细胞越来越多地被认为在PH病变发生过程中发挥着关键作用.
研究的目的:
- 审查PH中肺动脉偶然性纤维细胞的异常表型.
- 讨论推动这些激活纤维细胞表型的分子信号通路.
- 突出新型PH治疗目标的研究领域.
主要方法:
- 关于肺高血压和纤维细胞生物学的最新科学文献的综述.
- 对PH中纤维细胞激活的基础细胞和分子机制的分析.
- 确定涉及纤维细胞驱动PH的关键信号通路.
主要成果:
- 肺动脉偶然性纤维细胞在PH中表现出早期,明显和持续的增殖,抗亡和炎症反应.
- 这些纤维细胞对血管重塑和疾病进展做出了重大贡献.
- 特定的分子通路被确定为异常纤维细胞行为的关键驱动因素.
结论:
- 肺动脉偶然性纤维细胞是PH病变的核心参与者.
- 针对激活的纤维细胞表型及其信号通路为PH治疗提供了潜力.
- 需要进一步的研究,以充分阐明这些机制,并开发有效的治疗方法.
相关概念视频
Introduction to Fibroblasts
3.1K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.1K
Pulmonary Hypertension: Classification and Pathogenesis
168
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
168
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166


